Iovance [IOVA] vs Regeneron [REGN] Detailed Stock Comparison
Iovance
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Iovance wins in 7 metrics, Regeneron wins in 11 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Iovance | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.64 | 14.37 | Iovance |
| Price-to-Book Ratio | 1.12 | 1.98 | Iovance |
| Debt-to-Equity Ratio | 7.00 | 9.04 | Iovance |
| PEG Ratio | -3.15 | 12.57 | Iovance |
| EV/EBITDA | -1.52 | 12.20 | Iovance |
| Profit Margin (TTM) | -176.49% | 31.37% | Regeneron |
| Operating Margin (TTM) | -245.77% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | N/A | 29.64% | N/A |
| Return on Equity | -51.85% | 15.34% | Regeneron |
| Return on Assets (TTM) | -27.14% | 6.66% | Regeneron |
| Free Cash Flow (TTM) | $-364.05M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | -78.73% | -50.23% | Regeneron |
| Price-to-Sales Ratio (TTM) | 4.05 | 4.25 | Iovance |
| Enterprise Value | $555.56M | $54.50B | Regeneron |
| EV/Revenue Ratio | 2.61 | 3.83 | Iovance |
| Gross Profit Margin (TTM) | -0.85% | 85.58% | Regeneron |
| Revenue per Share (TTM) | $1 | $133 | Regeneron |
| Earnings per Share (Diluted) | $-1.22 | $39.66 | Regeneron |
| Beta (Stock Volatility) | 0.88 | 0.33 | Regeneron |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Iovance vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Iovance | -20.08% | -21.27% | 19.21% | -33.44% | -60.34% | -72.91% |
| Regeneron | 0.57% | 0.74% | 2.78% | 2.80% | -18.45% | -21.28% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Iovance | -78.73% | -83.33% | -92.41% | -70.49% | -98.08% | -98.08% |
| Regeneron | -50.23% | -10.45% | -8.09% | -2.31% | 2,289.64% | 6,594.41% |
Performance & Financial Health Analysis: Iovance vs Regeneron
| Metric | IOVA | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $861.55M | $60.39B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 18,797,860 | 917,617 |
| 90 Day Avg. Volume | 20,690,350 | 931,976 |
| Last Close | $2.11 | $563.00 |
| 52 Week Range | $1.64 - $12.51 | $476.49 - $1,211.20 |
| % from 52W High | -83.13% | -53.52% |
| All-Time High | $165.00 (Jun 06, 2011) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -98.72% | -53.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 67.99% | 0.04% |
| Quarterly Earnings Growth | 67.98% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | -1.76% | 0.31% |
| Operating Margin (TTM) | -2.46% | 0.30% |
| Return on Equity (TTM) | -0.52% | 0.15% |
| Debt to Equity (MRQ) | 7.00 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.30 | $287.55 |
| Cash per Share (MRQ) | $1.08 | $72.04 |
| Operating Cash Flow (TTM) | $-334,392,000 | $4.74B |
| Levered Free Cash Flow (TTM) | $-184,756,624 | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: Iovance vs Regeneron
| Metric | IOVA | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.64 | 14.37 |
| Forward P/E | -3.15 | 12.57 |
| PEG Ratio | -3.15 | 12.57 |
| Price to Sales (TTM) | 4.05 | 4.25 |
| Price to Book (MRQ) | 1.12 | 1.98 |
| Market Capitalization | ||
| Market Capitalization | $861.55M | $60.39B |
| Enterprise Value | $555.56M | $54.50B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.61 | 3.83 |
| Enterprise to EBITDA | -1.52 | 12.20 |
| Risk & Other Metrics | ||
| Beta | 0.88 | 0.33 |
| Book Value per Share (MRQ) | $2.30 | $287.55 |
Financial Statements Comparison: Iovance vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IOVA | REGN |
|---|---|---|
| Revenue/Sales | $49.32M | $3.03B |
| Cost of Goods Sold | $49.74M | $464.30M |
| Gross Profit | $-417,000 | $2.56B |
| Research & Development | $76.88M | $1.34B |
| Operating Income (EBIT) | $-121.22M | $591.70M |
| EBITDA | $-110.16M | $900.90M |
| Pre-Tax Income | $-118.00M | $905.00M |
| Income Tax | $-1.84M | $96.30M |
| Net Income (Profit) | $-116.16M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IOVA | REGN |
|---|---|---|
| Cash & Equivalents | $171.67M | $3.09B |
| Total Current Assets | $512.65M | $17.57B |
| Total Current Liabilities | $122.69M | $3.57B |
| Long-Term Debt | $44.22M | $2.70B |
| Total Shareholders Equity | $767.87M | $29.39B |
| Retained Earnings | $-2.50B | $32.38B |
| Property, Plant & Equipment | $82.32M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IOVA | REGN |
|---|---|---|
| Operating Cash Flow | $-100.65M | $1.36B |
| Capital Expenditures | $-6.21M | N/A |
| Free Cash Flow | $-109.91M | $773.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | IOVA | REGN |
|---|---|---|
| Shares Short | 98.63M | 2.07M |
| Short Ratio | 8.04 | 2.06 |
| Short % of Float | 0.32% | 0.02% |
| Average Daily Volume (10 Day) | 18,797,860 | 917,617 |
| Average Daily Volume (90 Day) | 20,690,350 | 931,976 |
| Shares Outstanding | 305.25M | 109.62M |
| Float Shares | 280.26M | 98.02M |
| % Held by Insiders | 0.00% | 0.02% |
| % Held by Institutions | 0.81% | 0.94% |
Dividend Analysis & Yield Comparison: Iovance vs Regeneron
| Metric | IOVA | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |